Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients
Eligibility criteria
This trial accepts healthy volunteersQualifiers
adult patients with suspected pneumocystis
with an indication for bronchial fibroscopy for BAL or induced sputum
no opposition to the research from the adult patient or his or her next of kin research for patients unable to express their non-opposition
Disqualifiers
Pneumocystis treated for more than 72 hours
pregnancy/breast-feeding
adult patients deprived of liberty, protected
Trial population
Adult patients with suspected pneumocystis
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Biological sampling
Other interventionMouthwash, nasopharyngeal swab, blood sampling
Treatment groups
240 Participants
are divided into 1 treatment groupGroup A: Adults with suspicion of pneumocystis1 intervention
Trial outcomes
Primary outcomes
1
Pearson correlation coefficient
Pearson correlation coefficient between the fungal load obtained by PCR on nasopharyngeal swabs nasopharyngeal swab and buccal lavage and that obtained by reference samples (induced sputum or BAL) in patients with confirmed PcP.
Time frame
At inclusionSecondary outcomes
1
Fungal load by qPCR
Quantitative fungal load results obtained by qPCR on nasopharyngeal swab, mouthwash, induced sputum, BAL
Time frame
At inclusion2
Fungal load by serum PCR
Quantitative fungal load results obtained by serum PCR
Time frame
At inclusion3
Beta D glucan blood levels
Time frame
At inclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov